NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $1.64 | Prev. Close $1.65 | Circuit Range N/A |
Day Range $1.60 - $1.80 | Year Range $0.40 - $15.61 | Volume 1,651 |
Average Traded $1.65 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Jun-26 | $1.64 | $1.80 | +0.00% |
29-Jun-26 | $1.64 | $1.80 | +9.09% |
26-Jun-26 | $1.61 | $1.65 | -1.79% |
25-Jun-26 | $1.70 | $1.68 | -5.88% |
24-Jun-26 | $1.76 | $1.78 | -0.28% |
23-Jun-26 | $1.69 | $1.79 | +2.29% |
22-Jun-26 | $1.77 | $1.75 | -13.58% |